TITLE

Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials

AUTHOR(S)
Perez, Edith A.; Koehler, Maria; Bryne, Julie; Preston, Alaknanda J.; Rappold, Erica; Ewer, Michael S.
PUB. DATE
June 2008
SOURCE
Mayo Clinic Proceedings;Jun2008, Vol. 83 Issue 6, p679
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
OBJECTIVE: To analyze the cardiac safety of lapatinib, an oral, reversible, tyrosine kinase EGFR (ERBB1) and HER2 inhibitor, using prospective data collected in 44 clinical studies. PATIENTS AND METHODS: Lapatinib (as monotherapy or in combination) was administered to 3689 patients in studies conducted between January 5, 2001, and September 30, 2006. Left ventricular ejection fraction (LVEF) was prospectively evaluated via multiple-gated acquisition scan or echocardiography at screening, every 8 weeks during therapy, and at withdrawal. We analyzed cardiac events defined as symptomatic (grade 3 or 4 left ventricular systolic dysfunction according to the National Cancer Institute Common Terminology Criteria for Adverse Events) or asymptomatic (LVEF decreases ≥20% relative to baseline and below the institution's lower limit of normal; no symptoms). RESULTS: A study-defined cardiac event was reported in 60 patients (1.6%) previously treated with anthracyclines (n=12), trastuzumab (n=14), or neither (n=34). These prior treatments were associated with a 2.2%, 1.7%, and 1.5% incidence of cardiac events, respectively. In most patients (53 patients, 83%), events were not preceded by symptoms. Mean times to onset and duration of LVEF decrease were 13.0 and 7.3 weeks, respectively. The decrease in LVEF was rarely severe; the mean nadir was 43%. In 40 patients for whom outcome was determined, 35 (88%) had a partial or full recovery regardless of continuation or discontinuation of lapatinib. No cardiac deaths occurred among patients treated with lapatinib. CONCLUSION: Our review of data from 44 clinical studies revealed low levels of cardiotoxicity for lapatinib. Cardiac events were usually asymptomatic, caused reversible decreases in LVEF, and occurred at similar rates in patients who were and were not pretreated with anthracyclines or trastuzumab.
ACCESSION #
32617216

 

Related Articles

  • From Single- to Multi-Target Drugs in Cancer Therapy: When Aspecificity Becomes an Advantage. Giordano, S.; Petrelli, A. // Current Medicinal Chemistry;2008, Vol. 15 Issue 5, p422 

    Targeted therapies by means of compounds that inhibit a specific target molecule represent a new perspective in the treatment of cancer. In contrast to conventional chemotherapy which acts on all dividing cells generating toxic effects and damage of normal tissues, targeted drugs allow to hit,...

  • Trastuzumab-DM1: A Clinical Update of the Novel Antibody-Drug Conjugate for HER2-Overexpressing Breast Cancer. Barginear, Myra F.; John, Veena; Budman, Daniel R. // Molecular Medicine;nov2012, Vol. 18 Issue 11, p1473 

    Trastuzumab is a monoclonal antibody targeted against the HER2 tyrosine kinase receptor. Although trastuzumab is a very active agent in HER2-overexpressing breast cancer, the majority of patients with metastatic HER2-overexpressing breast cancer who initially respond to trastuzumab develop...

  • Effects of a human compact anti-ErbB2 antibody on gastric cancer. Fedele, Carmine; Carvalho, Silvia; Riccio, Gennaro; Paciello, Rolando; Laccetti, Paolo; Schmitt, Fernando; De Lorenzo, Claudia // Gastric Cancer;Jan2014, Vol. 17 Issue 1, p107 

    Background: Gastric cancer represents one of the most common causes of cancer deaths worldwide. Overexpression of ErbB2, a tyrosine kinase receptor involved in the pathogenesis of several human cancer types, has been reported also in gastric cancer. Thus, the inhibition of ErbB2 signal...

  • Epidermal Growth Factor Receptor as a Target for Anti-Cancer Agent Design. Jiangying Cao; Hao Fang; Binghe Wang; Chunhua Ma; Wenfang Xu // Anti-Cancer Agents in Medicinal Chemistry;2010, Vol. 10 Issue 6, p491 

    The epidermal growth factor (EGF) receptors, one family of protein tyrosine kinases (PTK), are promising targets for the cancer therapy. Many potential inhibitors including monoclonal antibodies (mAbs), reversible inhibitors and irreversible inhibitors have been developed. Some of them have been...

  • Expression of Her-2/neu in endometrial carcinoma and its relation with clinicopathological variables. Eldin, Hanaa O. Badr; Helmy, Wafaa H. A. // Egyptian Journal of Hospital Medicine;Sep2007, Vol. 28, p418 

    Objective and background: Her-2/neu tyrosine kinase has been implicated in the development and progression of several human cancers and is target for therapeutic intervention. Smaller studies suggest that Her-2/neu may be involved in the tumerogenesis of endometrial adenocarcinoma. The aim of...

  • Novel targeted agents for gastric cancer. Lian Liu; Ning Wu; Jin Li // Journal of Hematology & Oncology;2012, Vol. 5 Issue 1, p31 

    Abstract: Contemporary advancements have had little impact on the treatment of gastric cancer (GC), the world's second highest cause of cancer death. Agents targeting human epidermal growth factor receptor mediated pathways have been a common topic of contemporary cancer research, including...

  • Brèves de l'AERIO.  // Oncologie;Dec2012, Vol. 14 Issue 12, p687 

    No abstract available.

  • Anthocyanins inhibit trastuzumab-resistant breast cancer in vitro and in vivo. XIN LI; JINMEI XU; XI TANG; YILUN LIU; XIAOPING YU; ZHI WANG; WEIHUA LIU // Molecular Medicine Reports;2016, Vol. 13 Issue 5, p4007 

    Trastuzumab (Herceptin®) is a recombinant humanized monoclonal antibody that is targeted against the human epidermal growth factor receptor 2 (HER2) tyrosine kinase receptor. Trastuzumab has been successfully used to treat patients with HER2-positive breast cancer, which accounts for ~25% of...

  • Targeted Anti-Cancer Therapies for Renal Cancer. Amato, Robert J.; Jac, Jaroslaw // Drugs;2006, Vol. 66 Issue 17, p2161 

    In the past several years, significant advances in the underlying biological mechanisms of renal cell cancer, particularly the role of tumour angiogenesis, have permitted the design of molecularly targeted therapeutics. For this review, single-agent therapies inhibiting the following different...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics